“Our role is to have a positive impact on the lives of patients with poorly understood diseases. It drives every decision we make.”
Grew to more than 425 colleagues worldwide
Marked the first full year of launch for ARIKAYCE® (amikacin liposome inhalation suspension) in the U.S.
Opened a new, state-of-the-art global HQ in Bridgewater, NJ
Filed for ARIKAYCE approval in Europe and Japan